Close Menu

NEW YORK – OpGen announced on Wednesday preliminary fourth quarter revenue of $1.3 million, up nearly 63 percent compared to the previous year.

The infectious disease diagnostics firm, however, noted that preliminary fiscal year 2020 revenue was $5.2 million, down 13 percent from $6.0 million in 2019. OpGen's cash position was $13.3 million as of the end of 2020.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.